Li Ning, Dhilipkannah Pushpa, Jiang Feng
Department of Pathology, University of Maryland School of Medicine, 10 S. Pine St., Baltimore, MD 21201, USA.
J Pers Med. 2021 Apr 29;11(5):359. doi: 10.3390/jpm11050359.
Altered miRNA expression and DNA methylation have highly active and diverse roles in carcinogenesis. Simultaneous detection of the molecular aberrations may have a synergistic effect on the diagnosis of malignancies. Herein, we develop a high-throughput assay for detecting multiple miRNAs and DNA methylation using droplet digital PCR (ddPCR) coupled with a 96-microwell plate. The microplate-based ddPCR could absolutely and reproducibly quantify 15 miRNAs and 14 DNA methylation sites with a high sensitivity (one copy/µL and 0.1%, respectively). Analyzing sputum and plasma of 40 lung cancer patients and 36 cancer-free smokers by this approach identified an integrated biomarker panel consisting of two sputum miRNAs (miRs-31-5p and 210-3p), one sputum DNA methylation (RASSF1A), and two plasma miRNAs (miR-21-5p and 126) for the diagnosis of lung cancer with higher sensitivity and specificity compared with a single type of biomarker. The diagnostic value of the integrated biomarker panel for the early detection of lung cancer was confirmed in a different cohort of 36 lung cancer patients and 39 cancer-free smokers. The high-throughput assay for quantification of multiple molecular aberrations across sputum and plasma could improve the early detection of lung cancer.
微小RNA(miRNA)表达改变和DNA甲基化在致癌过程中发挥着高度活跃且多样的作用。同时检测这些分子异常可能对恶性肿瘤的诊断产生协同效应。在此,我们开发了一种高通量检测方法,利用液滴数字PCR(ddPCR)结合96孔板来检测多种miRNA和DNA甲基化。基于微孔板的ddPCR能够以高灵敏度(分别为每微升1个拷贝和0.1%)绝对且可重复地定量15种miRNA和14个DNA甲基化位点。通过该方法分析40例肺癌患者和36例无癌吸烟者的痰液和血浆,确定了一个综合生物标志物组合,包括两种痰液miRNA(miR-31-5p和210-3p)、一种痰液DNA甲基化(RASSF1A)以及两种血浆miRNA(miR-21-5p和126),用于肺癌诊断,与单一类型生物标志物相比,具有更高的灵敏度和特异性。在另一组由36例肺癌患者和39例无癌吸烟者组成的队列中,证实了该综合生物标志物组合对肺癌早期检测的诊断价值。用于定量痰液和血浆中多种分子异常的高通量检测方法可改善肺癌的早期检测。